Mitochondrial Disease — Research Summary
Printed from RareWays (rareways.com.au) on 5 April 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Mitochondrial dysfunction in chemical anemia: can nursing led exercise programs improve red blood cell production?
Yin Minqiang et al. — Hematology (Amsterdam, Netherlands) (31 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41933276/
- 2.
Phenotypic description and functional characterization of the mitochondrial disease associated with the SFXN4 gene.
Courtois Sarah et al. — Mitochondrion (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41713566/
- 3.
Dysregulated iron homeostasis Drives mitochondrial Injury and ferroptosis susceptibility in MELAS fibroblasts.
Lin Yu-Han et al. — Mitochondrion (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41687756/
- 4.
Short telomeres in mitochondrial DNA depletion disorders.
Dille Yumi et al. — Mitochondrion (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41679577/
- 5.
Homozygous MGME1 Variant in Turkish Siblings: First Reported Case With Successful Heart Transplantation, Expanding the Clinical Spectrum of MGME1 -Related Mitochondrial Disease.
Acikgoz Nazli Busra et al. — American journal of medical genetics. Part A (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41508548/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
The Natural History of Mitochondrial Diseases
Recruiting — Neuroscience Research Australia
https://clinicaltrials.gov/study/NCT06504433
- 2.
Digital Health Technology for People With Mitochondrial Disease
Recruiting — Na — Neuroscience Research Australia
https://clinicaltrials.gov/study/NCT06535646
- 3.
Unravelling Energy Issues Underpinning Low Energy Availability in High Performance Athletes
Recruiting — Na — Australian Catholic University
https://clinicaltrials.gov/study/NCT07026175
- 4.
A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia
Recruiting — Phase 1 — Design Therapeutics, Inc.
https://clinicaltrials.gov/study/NCT06874010
- 5.
Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy
Recruiting — Phase 1 — PYC Therapeutics
https://clinicaltrials.gov/study/NCT06970106
- 6.
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Recruiting — Sanford Health
https://clinicaltrials.gov/study/NCT01793168
- 7.
Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study
Recruiting — Friedreich's Ataxia Research Alliance
https://clinicaltrials.gov/study/NCT06016946
- 8.
A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old (BRAVE)
Recruiting — Phase 3 — Biogen
https://clinicaltrials.gov/study/NCT06953583
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Mitochondrial Disease
Mitochondrial Disease refers to a group of genetic disorders caused by mutations in mitochondrial or nuclear DNA that impair the mitochondria's ability to produce energy. Affecting approximately 1 in 5,000 Australians, it can cause a wide range of symptoms including muscle weakness, neurological problems, vision loss, and organ failure. Australia has world-leading research in this area.
Most Recent Research
INTRODUCTION: Chemical anemia, a common consequence of chemotherapy and environmental toxins, is conventionally attributed to bone marrow suppression. This traditional view may oversimplify the underlying pathology, potentially overlooking critical cellular mechanisms that could serve as novel therapeutic targets. OBJECTIVES: This review aims to (1) propose a paradigm shift in understanding chemical anemia by reframing it as a disorder of mitochondrial dysfunction within erythroid precursors and (2) evaluate the potential of structured exercise as a multi-targeted countermeasure to restore erythropoiesis by addressing this mitochondrial root cause. METHODS: We synthesized evidence from cellular, molecular, and clinical studies to trace the pathway from chemical exposure to erythroid failure. This review integrates data on mitochondrial integrity, oxidative stress, mtDNA damage, heme synthesis, and cell death pathways (ferroptosis/apoptosis). Subsequently, we analyzed the impact of exercise on key molecular regulators (PGC-1α, AMPK) and mitochondrial quality control to assess its therapeutic potential. RESULTS: The synthesis reveals that chemical agents disrupt erythroid maturation primarily by compromising mitochondrial function. This leads to an energetic crisis, stalled heme synthesis, and the activation of ferroptotic and apoptotic pathways, resulting in ineffective erythropoiesis independent of general marrow suppression. Structured exercise is identified as a powerful physiological intervention that activates PGC-1α and AMPK, promoting mitochondrial biogenesis, enhancing mitophagy, and reducing oxidative stress, thereby directly counteracting the proposed pathogenic mechanism. DISCUSSION: By acting as a 'exercise mimetic,' physical activity offers a multi-targeted approach to restore mitochondrial health in erythroid precursors. Nurse-led exercise programs are uniquely positioned to translate this biological rationale into practice. By integrating aerobic and resistance training with patient safety monitoring and technology, nurses can operationalize exercise as a pragmatic, patient-centered, mitochondrial-supportive therapy. CONCLUSION: Reframing chemical anemia as a mitochondrial disorder highlights critical therapeutic vulnerabilities. Structured exercise, delivered through nurse-led programs, represents a promising complementary approach that targets the root cause of ineffective erythropoiesis, offering the potential to improve red blood cell production and reduce reliance on traditional interventions like transfusions and pharmacotherapy.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.